ライフサイエンスコーパス: cholangiopathy

1 ll of diverse pathologic processes (i.e. the cholangiopathies).

2 chanistic aspects of a virus induced biliary cholangiopathy.

3 tular proliferation that are associated with cholangiopathy.

4 is a chronic, idiopathic, fibroinflammatory cholangiopathy.

5 determining the likelihood of posttransplant cholangiopathy.

6 hs posttransplantation showed no evidence of cholangiopathy.

7 disease and cystic fibrosis (CF)-associated cholangiopathy.

8 ry end point was the development of ischemic cholangiopathy.

9 s developed liver disease with features of a cholangiopathy.

10 used to develop therapies for CF-associated cholangiopathy.

11 ose rotavirus strains that cause obstructive cholangiopathy.

12 s and is associated with development of AIDS cholangiopathy.

13 in one of the girls demonstrated a low grade cholangiopathy.

14 itor cell niche activation between these two cholangiopathies.

15 elevant to the pathogenesis of several human cholangiopathies.

16 related liver disease and other inflammatory cholangiopathies.

17 inhibits these processes and contributes to cholangiopathies.

18 be important in developing therapeutics for cholangiopathies.

19 iary proliferation/damage that is typical of cholangiopathies.

20 rella may lead to the development of chronic cholangiopathies.

21 y HCO3- umbrella might predispose to chronic cholangiopathies.

22 ating cholangiocytes and how this relates to cholangiopathies.

23 y tract destruction found in immune-mediated cholangiopathies.

24 and thus jointly contribute to AIDS-related cholangiopathies.

25 ht open new approaches for the management of cholangiopathies.

26 in the vicinity of the bile ducts in immune cholangiopathies.

27 ss that leads to these infantile obstructive cholangiopathies.

28 e (1239 vs 2065 U/L, P = 0.02), intrahepatic cholangiopathy (0% vs 22%, P = 0.015), biliary complicat

29 1; P: < 0.0001 and P: < 0.04) or obstructive cholangiopathy (7 +/- 7% and 0.7 +/- 0.6; P: < 0.006 and

30 epresent an important target of study in the cholangiopathies, a group of genetic developmental and a

31 vide the framework for new therapies for the cholangiopathies, a group of important hepatobiliary dis

32 ystic liver disease (PLD) is a member of the cholangiopathies, a group of liver diseases in which cho

33 vel therapeutic targets for the treatment of cholangiopathies and cholangiocarcinoma.

34 may represent a novel approach for treating cholangiopathy and comorbidities.

35 ., acquired immunodeficiency syndrome (AIDS) cholangiopathy and graft-versus-host disease (GVHD).

36 th acquired immunodeficiency syndrome (AIDS) cholangiopathy and occurs almost exclusively in adult pa

37 g theater, although higher rates of ischemic cholangiopathy and worse graft survival were still obser

38 d in most instances were preceded by chronic cholangiopathy and/or cirrhosis.

39 s, alcoholic liver disease, viral hepatitis, cholangiopathies, and hepatobiliary malignancies are emp

40 Three DCD liver recipients developed cholangiopathy, and this was associated with an inabilit

41 Cholangiopathies are a diverse group of progressive dise

42 The cholangiopathies are a group of hepatobiliary diseases i

43 Cholangiopathies are characterized by impaired cholangio

44 ltifactorial, with obliterative extrahepatic cholangiopathy as the common endpoint.

45 rease commonly seen with chronic obstructive cholangiopathy, because of less hepatocyte proliferation

46 ular connectivity among the three main human cholangiopathies (biliary atresia [BA], primary biliary

47 t to investigate the role of HAI-1 and -2 in cholangiopathies by exploring their functions in fetal l

48 sults demonstrate the potential for treating cholangiopathy by safely harnessing FGF19 biology to sup

49 tis can be challenging because other chronic cholangiopathies can present similarly; however, the dis

50 biliary cholangitis (PBC) are human primary cholangiopathies characterized by the damage of mature c

51 uct epithelia are the target of a number of "cholangiopathies" characterized by disordered bile ductu

52 is an inflammatory, fibrosclerosing neonatal cholangiopathy, characterized by a periductal infiltrate

53 21%; P < 0.001) and, specifically, ischemic cholangiopathy (DCD 44% vs. DBD 1.6%; P < 0.001) occurre

54 ngitis (PSC) is a chronic, fibroinflammatory cholangiopathy (disease of the bile ducts) of unknown pa

55 In other selective cholangiopathies, ductular cells positive for HAI-1 or H

56 h biliary atresia, the most common childhood cholangiopathy, exhibit increased levels of Th2-promotin

57 olangitis (IRSC), to the spectrum of chronic cholangiopathies has created the clinical need for relia

58 ry atresia are thought to be immune-mediated cholangiopathies, however, gaps in knowledge remain with

59 DCD: 47% vs DBD: 26%; P < 0.01) and ischemic cholangiopathy (IC) (DCD: 34% vs DBD: 1%; P < 0.01) were

60 Concerns for ischemic cholangiopathy (IC), a disease of diffuse intrahepatic s

61 ociated with a greater incidence of ischemic cholangiopathy (IC), leading to several programs to aban

62 the time of procurement to minimize ischemic cholangiopathy (IC).

63 ug VX809 rescues the disease phenotype of CF cholangiopathy in vitro.

64 langiocytes will have broad applications for cholangiopathies, in disease modeling and for screening

65 are thought to influence the progression of cholangiopathies, in particular primary sclerosing chola

66 ment of biliary damage and liver fibrosis in cholangiopathies including PSC.

67 y epithelium physiology and in non-malignant cholangiopathies is far from complete.

68 s of the inflammatory processes in fibrosing cholangiopathies is highlighted.

69 ies in the susceptibility to immune-mediated cholangiopathies is reviewed.

70 y of intrahepatic bile ducts and progressive cholangiopathy lead to end-stage cirrhosis.

71 gitis and acquired immunodeficiency syndrome cholangiopathy, MRCP depicted the biliary tract as clear

72 Neither ischemic cholangiopathy nor vascular complications occurred in th

73 Biliary atresia (BA) is a destructive cholangiopathy of childhood in which Th1 immunity has be

74 Biliary atresia is the most common cholangiopathy of childhood.

75 ft survival and higher incidence of ischemic cholangiopathy of DCD compared with DBD recipients were

76 Biliary atresia is an obliterative cholangiopathy of infancy that is fatal if untreated.

77 Biliary atresia (BA) is a neonatal cholangiopathy of unknown etiology.

78 sclerosing cholangitis (PSC) is an incurable cholangiopathy of unknown etiopathogenesis.

79 rome, which is characterized by a congenital cholangiopathy of variable severity.

80 s should be considered at increased risk for cholangiopathy or malignancy.

81 No graft failure due to intrahepatic cholangiopathy or nonfunction occurred in HOPE-treated l

82 were increased for recipients with ischemic cholangiopathy or retransplantation by 53% (P = 0.01) an

83 spholipid flippase, cause a wide spectrum of cholangiopathy phenotypes in humans.

84 asis and primary sclerosing cholangitis, two cholangiopathies regarded as risk factors for CCA.

85 ver, the mechanisms of pathogen-induced AIDS cholangiopathy remain unclear.

86 ity from chronic biliary diseases (i.e., the cholangiopathies) remains substantial.

87 nd acquired diseases of the biliary tree, or cholangiopathies, represent a significant source of morb

88 Human cholangiopathies share pathways enriched by immunity gen

89 histological, and clinical features of human cholangiopathies such as progressive familial intrahepat

90 The biliary tree is the target of cholangiopathies that are chronic cholestatic liver dise

91 atresia (BA) is a progressive, inflammatory cholangiopathy that culminates in fibrosis of extrahepat

92 rosing cholangitis is a chronic, progressive cholangiopathy that frequently affects men and is associ

93 brosis-associated liver disease is a chronic cholangiopathy that negatively affects the quality of li

94 Biliary atresia is a fibro-inflammatory cholangiopathy that obstructs the extrahepatic bile duct

95 liary atresia (BA) is a neonatal obstructive cholangiopathy that progresses to end-stage liver diseas

96 Biliary atresia is a neonatal obstructive cholangiopathy that progresses to end-stage liver diseas

97 tes in human cholestatic liver diseases (ie, cholangiopathies) that are characterized by ductular rea

98 sodeoxycholic acid (UDCA) is widely used for cholangiopathy treatment, but its effects on cholangiocy

99 ased odds of IC (95% CI = 4.8-24.2).Ischemic cholangiopathy was present in 16% of DCD compared with 3

100 cidences of acute kidney injury and ischemic cholangiopathy were greater in DCD recipients (32.6% vs.

101 ement causes injuries including intrahepatic cholangiopathy, which may lead to graft loss.

102 I-1 and -2 are overexpressed in the liver in cholangiopathies with ductular reactions and are possibl